These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 10090527)

  • 1. Evaluation of the thrombin inhibitor D-phenylalanyl-L-prolyl-L-arginine chloromethylketone (PPACK) with the factor Xa inhibitor 1,5-dansyl-L-glutamyl-L-glycyl-L-arginine chloromethylketone (GGACK) as anticoagulants for critical care clinical chemistry specimens.
    Lyon ME; Drobot DW; Harding SR; Lyon AW
    Clin Chim Acta; 1999 Feb; 280(1-2):91-9. PubMed ID: 10090527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of thrombin inhibitors ex vivo allows critical care clinical chemistry and hematology testing on common specimens.
    Lyon AW; Harding SR; Drobot D; Lyon ME
    Clin Biochem; 1997 Mar; 30(2):121-7. PubMed ID: 9127693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. D-phenylalanyl-L-prolyl-L-arginine chloromethyl ketone (PPACK): alternative anticoagulant to heparin salts for blood gas and electrolyte specimens.
    Lyon ME; Fine JS; Henderson PJ; Lyon AW
    Clin Chem; 1995 Jul; 41(7):1038-41. PubMed ID: 7600685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antithrombin nanoparticles inhibit stent thrombosis in ex vivo static and flow models.
    Palekar RU; Vemuri C; Marsh JN; Arif B; Wickline SA
    J Vasc Surg; 2016 Nov; 64(5):1459-1467. PubMed ID: 26482989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antithrombotic and hemostatic capacity of factor Xa versus thrombin inhibitors in models of venous and arteriovenous thrombosis.
    Sinha U; Ku P; Malinowski J; Zhu BY; Scarborough RM; Marlowe CK; Wong PW; Lin PH; Hollenbach SJ
    Eur J Pharmacol; 2000 Apr; 395(1):51-9. PubMed ID: 10781674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Agglutination of rabbit platelets in plasma by the thrombin inhibitor D-phenylalanyl-L-prolyl-L-arginyl chloromethyl ketone.
    Packham MA; Bryant NL; Guccione MA
    Thromb Haemost; 1990 Apr; 63(2):282-5. PubMed ID: 2363129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reproducibility and temporal stability of ADP-induced platelet aggregation: comparison of the anticoagulants sodium citrate and D-phenylalanyl-L-prolyl-L-arginyl-chloromethyl ketone.
    Horne WC; Anderson GM; Cohen DJ
    Am J Hematol; 1991 Sep; 38(1):48-53. PubMed ID: 1897514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anticoagulants (thrombin inhibitors) and aspirin synergize with P2Y12 receptor antagonism in thrombosis.
    André P; LaRocca T; Delaney SM; Lin PH; Vincent D; Sinha U; Conley PB; Phillips DR
    Circulation; 2003 Nov; 108(21):2697-703. PubMed ID: 14597584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The in vitro production of thromboxane B2 by platelets of diabetic patients is normal at physiological concentrations of ionized calcium.
    Falcon CR; Cattaneo M; Ghidoni A; Mannucci PM
    Thromb Haemost; 1993 Sep; 70(3):389-92. PubMed ID: 8259535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PPACK-thrombin inhibits thrombin-induced platelet aggregation and cytoplasmic acidification but does not inhibit platelet shape change.
    Greco NJ; Tenner TE; Tandon NN; Jamieson GA
    Blood; 1990 May; 75(10):1989-90. PubMed ID: 2337670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thrombin inhibitors and anti-coagulants on thrombin-induced embolisation in rabbit cranial vasculature.
    Liu JT; Paul W; Emerson M; Cicala C; Page CP
    Eur J Pharmacol; 1994 Oct; 264(2):183-90. PubMed ID: 7851481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of Thrombin With PPACK-Nanoparticles Restores Disrupted Endothelial Barriers and Attenuates Thrombotic Risk in Experimental Atherosclerosis.
    Palekar RU; Jallouk AP; Myerson JW; Pan H; Wickline SA
    Arterioscler Thromb Vasc Biol; 2016 Mar; 36(3):446-55. PubMed ID: 26769047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disseminated intravascular coagulation following Echis carinatus venom in dogs: effects of a synthetic thrombin inhibitor.
    Schaeffer RC; Briston C; Chilton SM; Carlson RW
    J Lab Clin Med; 1986 Jun; 107(6):488-97. PubMed ID: 3086470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of activated porcine factor IX by dansyl-glutamyl-glycyl-arginyl-chloromethylketone.
    Lollar P; Fass DN
    Arch Biochem Biophys; 1984 Sep; 233(2):438-46. PubMed ID: 6435527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of blood withdrawal and anticoagulant on clotting activity, hematologic data, and certain rheologic measurements.
    Reinhart WH; Haeberli A; Stark J; Straub PW
    J Lab Clin Med; 1990 Jan; 115(1):98-103. PubMed ID: 2105367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The antithrombotic effect of low molecular weight synthetic thrombin inhibitors, argatroban and PPACK, on He-Ne laser-induced thrombosis in rat mesenteric microvessels.
    Yamashita T; Yamamoto J; Sasaki Y; Matsuoka A
    Thromb Res; 1993 Jan; 69(1):93-100. PubMed ID: 8465278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacodynamics and pharmacokinetics of eptifibatide in patients with acute coronary syndromes: prospective analysis from PURSUIT.
    Tardiff BE; Jennings LK; Harrington RA; Gretler D; Potthoff RF; Vorchheimer DA; Eisenberg PR; Lincoff AM; Labinaz M; Joseph DM; McDougal MF; Kleiman NS;
    Circulation; 2001 Jul; 104(4):399-405. PubMed ID: 11468200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. D-Phe-Pro-Arg-chloromethylketone: its potential use in inhibiting the formation of in vitro artifacts in blood collected during tissue-type plasminogen activator thrombolytic therapy.
    Mohler MA; Refino CJ; Chen SA; Chen AB; Hotchkiss AJ
    Thromb Haemost; 1986 Oct; 56(2):160-4. PubMed ID: 2433785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of alcohol withdrawal on responses of platelets from alcoholics--a study using platelet-rich plasma from blood anticoagulated with D-phenylalanyl-L-prolyl-L-arginyl chloromethyl ketone (FPRCH2Cl).
    Rand ML; Neiman J; Jakowec DM; Packham MA
    Thromb Haemost; 1990 Apr; 63(2):178-82. PubMed ID: 2363118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional characterisation of vizottin, the first factor Xa inhibitor purified from the leech Haementeria vizottoi.
    Oliveira DG; Alvarez-Flores MP; Lopes AR; Chudzinski-Tavassi AM
    Thromb Haemost; 2012 Sep; 108(3):570-8. PubMed ID: 22782262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.